THE US FDA has approved Vabomere (meropenem/vaborbactam), a new antibacterial drug for the treatment of adults with complicated urinary tract infections (cUTIs).
Vabomere was designated for priority review under the FDA's Generating Antibiotic Incentives Now (GAIN) initiative.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Sep 17